The Australian Immunisation Handbook 10th Edition

01 August 2017

Page last updated: 01 August 2017

01 August 2017

Updates to the 10th edition of The Australian Immunisation Handbook

Advice included in the 10th edition of The Australian Immunisation Handbook has been updated since this edition was first published in 2013. A list of updates is provided below by the date they were published. These updates have been made in response to specific issues requiring amendment; amended chapters have not been reviewed in their entirety unless specified.

The most up-to-date version of the 10th edition Handbook is the online version. If you have a hard copy of the 10th edition Handbook this list can be printed for easy reference or used to annotate updates in your hard copy.

Key updates made to the 10th edition Handbook in August 2017 are listed below by chapter, including chapter sections and subsections. Other minor amendments to those listed below have been made to improve clarity, consistency and accuracy; these changes are not specifically noted. References have been removed, updated or introduced where required.

Note: The updated chapters are available online in HTML and PDF formats.

Chapter 2.1 Pre-vaccination

2.1.5 Catch-up

  • The text has been edited due to the discontinuation of the Haemophilus b conjugate (PRP-OMP) vaccine in Australia (PedvaxHIB). (Refer also Chapter 4.3 Haemophilus influenzae type b).

Chapter 3.3 Groups with special vaccination requirements

3.3.2 Vaccination of women who are planning pregnancy, pregnant or breastfeeding, and preterm infants

  • Clarification of advice on the administration dTpa during the third trimester of each pregnancy.

3.3.3 Vaccination of immunocompromised persons

  • Addition of text and a table to clarify the contraindications to use of zoster vaccine in immunocompromised individuals and to provide further detail on what constitutes immunocompromise relevant to all live vaccines. (Refer also Chapter 4.24 Zoster).
  • Addition of text providing more specific detail of CD4 levels at which a person infected with HIV can receive zoster vaccine. (Refer also Chapter 4.24 Zoster).

3.3.7 Vaccination of persons at occupational risk

  • Addition of text clarifying diphtheria vaccination in laboratory workers. (Refer also Chapter 4.2 Diphtheria).

Chapter 4.2 Diphtheria

4.2.4 Vaccines and 4.2.12 Variations from product information

4.2.7 Recommendations

  • Addition of text clarifying vaccination in laboratory workers.

Chapter 4.3 Haemophilus influenzae type b

4.3.4 Vaccines

  • Addition of text to clarify situations in which vaccine interchangeability will now need to be considered.

4.3.4 Vaccines, 4.3.7 Recommendations, 4.3.12 Variations from product information

Chapter 4.4 Hepatitis A

4.4.4 Vaccines

  • Amendment of text to align with new product information.

4.4.6 Dosage and administration

  • Correction of incorrect text, replacing ELISA units with antigen units and changing 12 months to 36 months.

Chapter 4.9 Measles

4.9.4 Vaccines

4.9.5 Transport, storage and handling

  • Amendment of text to align with new product information on storage of vaccine at various temperatures (Refer also Chapters, 4.11 Mumps and 4.18 Rubella).

4.9.10 Precautions, 4.9.11 Adverse events

4.9.11 Adverse events

  • Addition of text on ovalbumin quantity in vaccine.

Chapter 4.11 Mumps

4.11.4 Vaccines

4.11.5 Transport, storage and handling

  • Amendment of text to align with new product information on storage of vaccine at various temperatures (Refer also Chapters, 4.9 Measles and 4.18 Rubella).

4.11.11 Adverse events

Chapter 4.12 Pertussis

4.12.4 Vaccines and 4.12.12 Variations from product information

Chapter 4.14 Polio

4.14.4 Vaccines and 4.14.12 Variations from product information

Chapter 4.16 Rabies

4.16.5 Rabies immunoglobulin

  • Amendment of text relating to the use of immunoglobulin.

4.16.7 Dosage and administration

  • Clarification of text relating to administration of the vaccine and immunoglobulin.

4.16.8 Recommendations

  • Removal of text referring to exposure in an animal that has been dead for 4 hours or more. Addition of text clarify the need for a risk assessment of exposure which should take into account both live and dead animals.
  • Addition of text providing further detail and clarification regarding situations in which exposure may have occurred and a person may be unaware or unable to communicate this.

Chapter 4.17 Rotavirus

4.17.6 Dosage and administration

  • Amendment of text relating to the need for a third dose of vaccine.

Chapter 4.18 Rubella

4.18.4 Vaccines

4.18.5 Transport, storage and handling

  • Amendment of text to align with new product information on storage of vaccine at various temperatures (Refer also Chapters, 4.9 Measles and 4.11 Mumps).

4.18.11 Adverse events

Chapter 4.19 Tetanus

4.19.4 Vaccines and 4.19.12 Variations from product information

Chapter 4.20 Tuberculosis

4.20.10 Precautions

  • Addition of text to clarify when BCG vaccination should be deferred in people with skin conditions.

Chapter 4.21 Typhoid

4.21.4 Vaccines

Chapter 4.22 Varicella

4.22.4 Vaccines

4.22.11 Adverse events

4.22.12 Public health management of varicella

  • Addition of text to section regarding giving neonates zoster immunoglobulin (ZIG) to clarify it is after primary varicella-zoster virus (VZV) infection of the mother.

Chapter 4.23 Yellow fever

4.23.4 Vaccine

  • Amendment of text describing vaccine failure.

4.23.7 Recommendations

  • Editing of text relating to a booster dose to provide clarity.

Chapter 4.24 Zoster

4.24.7 Recommendations

  • Addition of text reiterating importance of obtaining a medical history in patients prior to vaccination, to reiterate the contraindications regarding use of zoster vaccine in immunocompromised individuals and to provide further detail on what constitutes immunocompromise and how to manage inadvertent vaccination in these individuals.

4.24.9 Contraindications

  • Addition of text and table to reiterate the contraindications regarding use of zoster vaccine in immunocompromised individuals and to provide further detail on what constitutes immunocompromise and how to manage inadvertent vaccination in these individuals.

4.24.10 Precautions

4.24.11 Adverse events

  • Addition of text providing details of select serious outcomes where immunocompromised individuals have received zoster vaccine.

Appendices 3 & 4